Approaches to preserve larynx function in locally advanced laryngeal and hypopharyngeal cancer

Onkologie

Volumn 27, Issue 4, 2004, Pages 368-375

  Rudat, V ^a   Pfreundner, L ^b   Hoppe, F ^c   Dietz, A ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Radiation Oncology ^*  (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Chemotherapy protocols, antineoplastic combined; Laryngectomy; Organ preservation: Larynx, hypopharynx; Radiotherapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; PLATINUM;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOTOXICITY; DOSE RESPONSE; GERMANY; HUMAN; HYPOPHARYNX CARCINOMA; LARYNGECTOMY; LARYNX CARCINOMA; META ANALYSIS; PREDICTION; RANDOMIZATION; REVIEW; SURGICAL TECHNIQUE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; LARYNGECTOMY; NEOADJUVANT THERAPY; NEOPLASM STAGING; PLATINUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 4644305942     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079090     Document Type: Review

References (78)

1. DeSanto LW, Olsen KD, Perry WC, Rohe DE, Keith RL: Quality of life after surgical treatment of cancer of the larynx. Ann Otol Rhinol Laryngol 1995;104:763-769.
2. Weinstein GS: Surgical approach to organ preservation in the treatment of cancer of the larynx. Oncology (Huntingt) 2001;15:785-796.
3. Kish JA, Weaver A, Jacobs J, Cummings G, Al Sarraf M: Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984;53:1819-1824.
4. Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, Cummings G, Al Sarraf M: Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984;54:811-814.
5. Hong WK, O'Donoghue GM, Sheetz S, Fofonoff S, Dorman EB, Welch J, Vaughan CW, Karp DD, Willett B, Strong S: Sequential response patterns to chemotherapy and radiotherapy in head and neck cancer: Potential impact of treatment in advanced laryngeal cancer. Prog Clin Biol Res 1985;201:191-197.
6. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-1690.
7. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899.
8. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-955.
9. Munro AJ: An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83-91.
10. Browman GP: Evidence-based recommendations against neoadjuvant chemotherapy for routine management of patients with squamous cell head and neck cancer. Cancer Invest 1994;12:662-670.
11. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 1998;16:1318-1324.
12. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
13. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
14. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000;18:1458-1464.
15. Dobrowsky W, Naude J: Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000;57:119-124.
16. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-1171.
17. Adelstein DJ, Li Y, Adams GL, Wagner H Jr., Kish JA, Ensley JF, Schuller DE, Forastiere AA: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
18. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
19. Koch WM: Head and neck surgery in the era of organ preservation therapy. Semin Oncol 2000;27:5-12.
20. Tufano RP: Organ preservation surgery for laryngeal cancer. Otolaryngol Clin North Am 2002;35:1067-1080.
21. Teknos TN, Hogikyan ND, Wolf GT: Conservation laryngeal surgery for malignant tumors of the larynx and pyriform sinus. Hematol Oncol Clin North Am 2001;15:261-276.
22. Laccourreye O, Salzer SJ, Brasnu D, Shen W, Laccourreye H, Weinstein GS: Glottic carcinoma with a fixed true vocal cord: Outcomes after neoadjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidoepiglottopexy. Otolaryngol Head Neck Surg 1996;114:400-406.
23. Laccourreye O, Brasnu D, Biacabe B, Hans S, Seckin S, Weinstein G: Neo-adjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidopexy for advanced endolaryngeal carcinoma classified as T3-T4: 5-year oncologic results. Head Neck 1998;20:595-599.
24. Choksi AJ, Dimery IW, Hong WK: Adjuvant chemotherapy of head and neck cancer: The past, the present, and the future. Semin Oncol 1988;15:45-59.
25. Mendenhall WM: T3-4 squamous cell carcinoma of the larynx treated with radiation therapy alone. Semin Radiat Oncol 1998;8:262-269.
26. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ: T4 laryngeal carcinoma: Radiotherapy alone with surgery reserved for salvage. Int J Radiat Oncol Biol Phys 1998;40:549-552.
27. Rudat V, Wannenmacher M: Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. Semin Surg Oncol 2001;20:66-74.
28. Bataini P, Brugere J, Bernier J, Jaulerry CH, Picot C, Ghossein NA: Results of radical radiotherapeutic treatment of carcinoma of the pyriform sinus: Experience of the institut curie. Int J Radiat Oncol Biol Phys 1982;8:1277-1286.
29. Castelijns JA, Golding RP, van Schaik C, Valk J, Snow GB: MR Findings of cartilage invasion by laryngeal cancer: Value in predicting outcome of radiation therapy. Radiology 1990;174:669-673.
30. Mendenhall WM, Parsons JT, Mancuso AA, Pameijer FJ, Stringer SP, Cassisi NJ: Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx. J Clin Oncol 1997;15:2394-2402.
31. Vermund H: Role of radiotherapy in cancer of the larynx as related to the TNM system of staging. A review. Cancer 1970;25:485-504.
32. Harwood AR, Beale FA, Cummings BJ, Keane TJ, Payne D, Rider WD: T4NOMO glottic cancer: An analysis of dose-time volume factors. Int J Radiat Oncol Biol Phys 1981;7:1507-1512.
33. Fletcher GH, Hamberger AD: Causes of failure in irradiation of squamous-cell carcinoma of the supraglottic larynx. Radiology 1974;111:697-700.
34. Fletcher GH, Jesse RH, Lindberg RD, Koons CR: The place of radiotherapy in the management of the squamous cell carcinoma of the supraglottic larynx. Am J Roentgenol Radium Ther Nucl Med 1970;108:19-26.
35. Isaacs JH Jr., Mancuso AA, Mendenhall WM, Parsons JT: Deep spread patterns in CT staging of T2-4 squamous cell laryngeal carcinoma. Otolaryngol Head Neck Surg 1988;99:455-464.
36. Wang CC, Montgomery WW: Deciding on optimal management of supraglottic carcinoma. Oncology (Huntingt) 1991;5:41-46.
37. Pameijer FA, Mancuso AA, Mendenhall WM, Parsons JT, Kubilis PS: Can pretreatment computed tomography predict local control in T3 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy? Int J Radiat Oncol Biol Phys 1997;37:1011-1021.
38. Rudat V, Dietz A, Schramm O, Conradt C, Maier H, Flentje M, Wannenmacher M: Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 1999;53:119-125.
39. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J, III, Wazer DE: The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 1995;32:635-641.
40. Mancuso AA, Mukherji SK, Schmalfuss I, Mendenhall W, Parsons J, Pameijer F, Hermans R, Kubilis P: Preradiotherapy computed tomography as a predictor of local control in supraglottic carcinoma. J Clin Oncol 1999;17:631-637.
41. Horiot JC, Bontemps P, van den BW, Le Fur R, van den WD, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-121.
42. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
43. Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, Stromboni-Luboinski M, Hill C: Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998;34:224-228.
44. Wolf GT: Options for preserving the larynx in patients with advanced laryngeal and hypopharyngeal cancer. Ear Nose Throat J 2001;80:897-901.
45. Hillman RE, Walsh MJ, Wolf GT, Fisher SG, Hong WK: Functional outcomes following treatment for advanced laryngeal cancer. Part I-Voice preservation in advanced laryngeal cancer. Part II-Laryngectomy rehabilitation: The state of the art in the VA system. Research speech-language pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl 1998;172:1-27.
46. Mohide EA, Archibald SD, Tew M, Young JE, Haines T: Postlaryngectomy quality-of-life dimensions identified by patients and health care professionals. Am J Surg 1992;164:619-622.
47. Terrell JE, Fisher SG, Wolf GT: Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 1998;124:964-971.
48. Forastiere AA: Larynx preservation trials: A critical appraisal. Semin Radiat Oncol 1998;8:254-261.
49. Tannock IF, Cummings BJ: Neoadjuvant chemotherapy in head and neck cancer: No way to preserve a larynx. J Clin Oncol 1992;10:343-345.
50. Harari PM: Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J Clin Oncol 1997;15:2050-2055.
51. Al Sarraf M, Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS: Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 1997;37:777-782.
52. Bernier J, Domenge C, Eschwege F, Ozsahin M, Matuszewska, K, Moncho V, Greiner RH, Giralt J, Kirkpatrick A, van Glabbeke M: Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck caner patients after surgery: Results of the EORTC Phase III Trial 22931. Int J. Radiat Oncol Biol Phys 2001;51:1.
53. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK, Laramore GE, Al Sarraf M: Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: Targets for postoperative radiochemotherapy? Head Neck 1998;20:588-594.
54. Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H, Morrison W, Glisson B, Trotti A, Ridge JA, Chao KS, Peters G, Lee DJ, Leaf A, Ensley J: Outcome of salvage total laryngectomy following organ preservation therapy: The Radiation Therapy Oncology Group Trial 91-11. Arch Otolaryngol Head Neck Surg 2003;129:44-49.
55. Dietz A, Nollert J, Eckel H, Volling P, Schroder M, Staar S, Conradt C, Helmke B, Dollner R, Muller RP, Wannenmacher M, Weidauer H, Rudat V: Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study. HNO 2002;50:146-154.
56. Pfreundner L, Hoppe F, Willner J, Preisler V, Bratengeier K, Hagen R, Helms J, Flentje M: Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas - a possibility for organ preservation. Radiother Oncol 2003;68:163-170.
57. Knecht R, Baghi M, Hambeck M, Tesch H, Gstottner W: Response rate and outcome of a novel induction chemotherapy regimen (TPF) in the firstline therapy of advanced head and neck carcinomas (SCCHN). Proc Am Soc Clin Oncol 2003; 22:501 (abstr 2017).
58. Hitt R, Paz-Ares L, Hidalgo M, Colomer R, Brandariz A, Pena M, Alvarez-Vicent J, Hornedo J, Cortes-Funes H: Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin Oncol 1997;24:S19.
59. Hitt R, Paz-Ares L, Brandariz A, Castellano D, Pena C, Millan JM, Calvo F, Ortiz DU, Lopez E, Alvarez-Vicent JJ, Cortes-Funes H: Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: Long-term results of a phase II trial. Ann Oncol 2002;13:1665-1673.
60. Dunphy FR, Dunleavy TL, Harrison BR, Trinkaus KM, Kim HJ, Stack BC Jr., Needles B, Boyd JH: Induction Paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer 2001;91:940-948.
61. Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, Lefantzis D, Dokianakis G: Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001;24:227-231.
62. Bradford CR, Wolf GT, Carey TE, Zhu S, Beals TF, Truelson JM, McClatchey KD, Fisher SG: Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg 1999;121:534-538.
63. Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, Singleton T, Wicha M: Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: Correlation with response to chemotherapy and organ preservation. Laryngoscope 2002;112:638-644.
64. Haas S, Bosch FX, Klein-Kuhne W, Nollert J, Rudat V, Conradt C, Dietz A: Prognostic significance of cell-cycle regulatory proteins for outcome after primary radiochemotherapy in patients with advanced head and neck cancer. HNO 1999;47:777-786.
65. Grabenbauer GG, Steininger H, Meyer M, Fietkau R, Brunner T, Heinkelmann P, Hornung J, Iro H, Spitzer W, Kirchner T, Sauer R, Distel L: Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol 1998;47:175-183.
66. Rudat V, Stadler P, Becker A, Vanselow B, Dietz A, Wannenmacher M, Molls M, Dunst J, Feldmann J: Predictive value of the tumor oxygenation by means of PO(2) histography in patients with advanced head and neck cancer. Strahlenther Onkol 2001;177:462-468.
67. Rudat V, Vanselow B, Wollensack P, Bettscheider C, Osman-Ahmet S, Eble MJ, Dietz A: Repeatability and prognostic impact of the pretreatment PO(2) histography in patients with advanced head and neck cancer. Radiother Oncol 2000;57:31-37.
68. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-39.
69. Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, Molls M: Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-754.
70. Wenz F, Lohr F, Flentje M, Rudat V, Dietz A, Wannenmacher M: Predictive value of the flow cytometric PCNA assay (proliferating cell nuclear antigen) in head and neck tumors after accelerated-hyperfractionated radiochemotherapy. Int J Radiat Oncol Biol Phys 1997;37:771-776.
71. Begg AC, Haustermans K, Hart AA, Dische S, Saunders M, Zackrisson B, Gustaffson H, Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink H, Horiot JC, Corvo R, Giaretti W, Awwad H, Shouman T, Jouffroy T, Maciorowski Z, Dobrowsky W, Struikmans H, Wilson GD: The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis. Radiother Oncol 1999;50:13-23.
72. Bjork-Eriksson T, West C, Karlsson E, Mercke C: Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol Biol Phys 2000;46:13-19.
73. Rudat V, Dietz A, Conradt C, Weber KJ, Flentje M: In vitro radiosensitivity of primary human fibroblasts. Lack of correlation with acute radiation toxicity in patients with head and neck cancer. Radiother Oncol 1997;43:181-188.
74. Rudat V, Dietz A, Nollert J, Conradt C, Weber KJ, Flentje M, Wannenmacher M: Acute and late toxicity, tumour control and intrinsic radiosensitivity of primary fibroblasts in vitro of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 1999;53:233-245.
75. Johansen J, Bentzen SM, Overgaard J, Overgaard M: Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother Oncol 1996;40:101-109.
76. Peacock J, Ashton A, Bliss J, Bush C, Eady J, Jackson C, Owen R, Regan J, Yarnold J: Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol 2000;55:173-178.
77. Berlangieri SU, Brizel DM, Scher RL, Schifter T, Hawk TC, Hamblen S, Coleman RE, Hoffman JM: Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 1994;16:340-346.
78. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El Ghazi EA, Lehmann W, Slosman DO: Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002;20:1398-1404.